Biopharma firm Biohaven's Q3 net loss widens to $173.4 mln

Biohaven

10/11/2025 12:06

Overview

Biohaven reports Q3 net loss of $173.4 mln, operating expenses at $169.4 mln

Company initiates strategic cost optimization to reduce annual direct R&D spend by 60%

Biohaven focuses resources on late-stage programs for epilepsy, depression, and immune diseases

Outlook

Biohaven expects top-line results from Opakalim Phase 2 study in depression in 4Q 2025

Company plans to initiate Phase 2 trial for Taldefgrobep alfa in obesity in 4Q 2025

Biohaven aims to reduce annual direct R&D spend by approximately 60%

Result Drivers

COST OPTIMIZATION - Biohaven initiated strategic cost optimization to focus on late-stage clinical programs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$173.44 mln
Q3 Basic EPS
-$1.64
Q3 Operating Expenses
$169.38 mln
Q3 Profit From Operations
-$169.38 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Biohaven Ltd is $27.00, about 69.4% above its November 7 closing price of $8.26

Press Release: ID:nPn8ktwCsa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)